Balaxi | Investor Contacts

ISR-4 [Request for issue of Duplicate Certificate and other Service Requests]

ISR-2 [Confirmation of Signature of securities holder by the Banker]

ISR-1 [Request for Registering PAN, KYC Details or changes thereof]

ISR-3 [Declaration Form for Opting-out of Nomination by holders of physical securities]

SH-13 [Nomination Form]

SH-14 [Cancellation or Variation of Nomination]

SEBI Circular on online resolution of disputes in the Indian Securities Market

Corrigendum cum Amendment to Circular dated July 31, 2023 on Online Resolution of Disputes in the Indian Securities Market

Frequently Asked Questions (FAQs) with respect to Investor Service Requests processed by Registrar to an Issue & Share Transfer Agents (RTAs)

The Shares of the Company are listed on the following Stock Exchanges: 

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1 G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400051 



For Investor Grievances, Please Contact:

Mr. Udayan Shukla

(Company Secretary and Compliance Officer)

Balaxi Pharmaceuticals Limited

Plot No.409, H. No: 8-2-293,
MAPS Towers, 3rd Floor,
Phase-III, Road No: 81, Jubilee Hills,
Hyderabad, Telangana, India, 500 096

Phone: +91 40 2355-5300

Email: [email protected]

Registrars & Share Transfer Agent:

Aarthi Consultants Private Limited

1-2-285, Domalguda,

Ph: 040-27638111, 27634445
Fax: 040-27632184

Email: [email protected]

Nodal Officer (For Unclaimed Dividend/ Shares):



Address and Contact Number

Email ID

Mr. Udayan Shukla

Company Secretary and Compliance Officer

Address: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase - III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) – 500 096.


Contact Number: +91 40 23555300


[email protected]



Link for the Smart Online Dispute Resolution Portal is as follows: 

Attention Physical Security Holders: 

SEBI, vide its circular dated November 03, 2021 (subsequently amended by circulars dated December 14, 2021, March 16, 2023 and November 17, 2023) mandated that the security holders (holding securities in physical form), whose folio(s) do not have PAN or Choice of Nomination or Contact Details or Mobile Number or Bank Account Details or Specimen Signature updated, shall be eligible for any payment including dividend, interest or redemption in respect of such folios, only through electronic mode with effect from April 01, 2024.

Further, relevant FAQs have also been published by SEBI on its website at the following web link for investor awareness: 



Investor Contact

Balaxi Pharmaceuticals Limited